Search

INTRODUCTION AND OBJECTIVES:Renal Cell Carcinoma is newly diagnosed in 58,000 individuals in the United States annually. Papillary Renal Cell Carcinoma (pRCC) is the second most common variant of r...

INTRODUCTION AND OBJECTIVES:Active surveillance (AS) is becoming the de facto standard of care for men with low risk prostate cancer. Due to various risk factors, certain groups of men are deemed t...

INTRODUCTION AND OBJECTIVES:Micro RNAs (miRNA) are short non-coding RNA which are associated with post-transcriptional regulation of gene expression. As clear cell renal cell carcinoma (ccRCC) rema...

INTRODUCTION AND OBJECTIVES:In the formation of cancer, DNA alterations known as “driver mutations” promote carcinogenesis, giving cells an invasive and malignant phenotype. One of the most common ...

Studies have suggested that statin (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors) medication use may decrease prostate specific antigen in healthy men. We determined the effect of preoperative statin use on total preoperative prostate specific antigen and the risk of biochemical recurrence in patients with prostate cancer presenting for radical prostatectomy.A retrospective review of 3,828 patients undergoing radical prostatectomy from January 2001 to July 2008 at our institution identified 1,031 on statin medications. We compared these 1,031 patients to the remaining 2,797 not on statins preoperatively. We evaluated differences in prostate specific antigen overall, and when patients were stratified by age specific groups, body mass index and Gleason grades on final pathology. We also investigated differences in biochemical recurrence rates.Overall median serum prostate specific antigen was lower in patients on preoperative statins (5.0 vs 5.2 ng/ml, p = 0.002). Median prostate specific antigen was lower in men on statins with Gleason grades 7 or 8/9 disease (p0.05). Using a multivariate logistic regression model statin therapy was associated with a 4.7% decrease in prostate specific antigen (p0.001). Statin therapy was not associated with an overall decreased risk of biochemical recurrence (p = 0.73) at a mean followup of 26 months.In this cohort of men presenting for radical prostatectomy serum prostate specific antigen is significantly lower in patients with prostate cancer on preoperative statins compared to those not taking these medications. Prospective studies are required to evaluate if this decrease in prostate specific antigen leads to later detection of prostate cancer or variations in oncological outcomes.